Genetically modified immune cells targeting tumor antigens
Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such ‘living’ therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Beside...
Gespeichert in:
| Veröffentlicht in: | Pharmacology & therapeutics (Oxford) 2020-10, Vol.214, p.107603-107603, Article 107603 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 107603 |
|---|---|
| container_issue | |
| container_start_page | 107603 |
| container_title | Pharmacology & therapeutics (Oxford) |
| container_volume | 214 |
| creator | Poorebrahim, Mansour Abazari, Mohammad Foad Sadeghi, Solmaz Mahmoudi, Reza Kheirollahi, Asma Askari, Hassan Wickström, Stina L. Poortahmasebi, Vahdat Lundqvist, Andreas Kiessling, Rolf Cid-Arregui, Angel |
| description | Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such ‘living’ therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy. |
| doi_str_mv | 10.1016/j.pharmthera.2020.107603 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_470418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163725820301339</els_id><sourcerecordid>2415294564</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-6e3fe0838d707e237cbcfed2ecf44017ce1cc72540b29a576bfaf2b72da3f1af3</originalsourceid><addsrcrecordid>eNqFkEtPwzAQhC0EEqXwH3LkkuJX4pQbVFCQKnEBiZvlOOvWJS9sB9R_j6NUcOQ0q9W3o9lBKCF4QTDJb_aLfqdcE3bg1IJiOq5FjtkJmpFCLNPIvJ-iWRSWCpoV5-jC-z3GmHNMZ-h2DS0Eq1VdH5Kmq6yxUCW2aYYWEg117ZOg3DYi7TYJQ9O5RLXBbqH1l-jMqNrD1VHn6O3x4XX1lG5e1s-ru02qOVuGNAdmABesqAQWQJnQpTZQUdAmRiBCA9E6JuO4pEuVibw0ytBS0EoxQ5Rhc5ROvv4b-qGUvbONcgfZKSuPq484geQCc1JE_nrie9d9DuCDbKwfX1EtdIOXlJOMLnmW84gWE6pd570D82tOsBzrlXv5V68c65VTvfH0fjqF-PqXBSe9ttBqqKwDHWTV2f9NfgD2yIp_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2415294564</pqid></control><display><type>article</type><title>Genetically modified immune cells targeting tumor antigens</title><source>SWEPUB Freely available online</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Poorebrahim, Mansour ; Abazari, Mohammad Foad ; Sadeghi, Solmaz ; Mahmoudi, Reza ; Kheirollahi, Asma ; Askari, Hassan ; Wickström, Stina L. ; Poortahmasebi, Vahdat ; Lundqvist, Andreas ; Kiessling, Rolf ; Cid-Arregui, Angel</creator><creatorcontrib>Poorebrahim, Mansour ; Abazari, Mohammad Foad ; Sadeghi, Solmaz ; Mahmoudi, Reza ; Kheirollahi, Asma ; Askari, Hassan ; Wickström, Stina L. ; Poortahmasebi, Vahdat ; Lundqvist, Andreas ; Kiessling, Rolf ; Cid-Arregui, Angel</creatorcontrib><description>Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such ‘living’ therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy.</description><identifier>ISSN: 0163-7258</identifier><identifier>EISSN: 1879-016X</identifier><identifier>DOI: 10.1016/j.pharmthera.2020.107603</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>Genetically modified immune cell ; Tumor antigen ; ‘Living’ therapy</subject><ispartof>Pharmacology & therapeutics (Oxford), 2020-10, Vol.214, p.107603-107603, Article 107603</ispartof><rights>2020 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-6e3fe0838d707e237cbcfed2ecf44017ce1cc72540b29a576bfaf2b72da3f1af3</citedby><cites>FETCH-LOGICAL-c439t-6e3fe0838d707e237cbcfed2ecf44017ce1cc72540b29a576bfaf2b72da3f1af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pharmthera.2020.107603$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,552,778,782,883,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:144681449$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Poorebrahim, Mansour</creatorcontrib><creatorcontrib>Abazari, Mohammad Foad</creatorcontrib><creatorcontrib>Sadeghi, Solmaz</creatorcontrib><creatorcontrib>Mahmoudi, Reza</creatorcontrib><creatorcontrib>Kheirollahi, Asma</creatorcontrib><creatorcontrib>Askari, Hassan</creatorcontrib><creatorcontrib>Wickström, Stina L.</creatorcontrib><creatorcontrib>Poortahmasebi, Vahdat</creatorcontrib><creatorcontrib>Lundqvist, Andreas</creatorcontrib><creatorcontrib>Kiessling, Rolf</creatorcontrib><creatorcontrib>Cid-Arregui, Angel</creatorcontrib><title>Genetically modified immune cells targeting tumor antigens</title><title>Pharmacology & therapeutics (Oxford)</title><description>Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such ‘living’ therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy.</description><subject>Genetically modified immune cell</subject><subject>Tumor antigen</subject><subject>‘Living’ therapy</subject><issn>0163-7258</issn><issn>1879-016X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>D8T</sourceid><recordid>eNqFkEtPwzAQhC0EEqXwH3LkkuJX4pQbVFCQKnEBiZvlOOvWJS9sB9R_j6NUcOQ0q9W3o9lBKCF4QTDJb_aLfqdcE3bg1IJiOq5FjtkJmpFCLNPIvJ-iWRSWCpoV5-jC-z3GmHNMZ-h2DS0Eq1VdH5Kmq6yxUCW2aYYWEg117ZOg3DYi7TYJQ9O5RLXBbqH1l-jMqNrD1VHn6O3x4XX1lG5e1s-ru02qOVuGNAdmABesqAQWQJnQpTZQUdAmRiBCA9E6JuO4pEuVibw0ytBS0EoxQ5Rhc5ROvv4b-qGUvbONcgfZKSuPq484geQCc1JE_nrie9d9DuCDbKwfX1EtdIOXlJOMLnmW84gWE6pd570D82tOsBzrlXv5V68c65VTvfH0fjqF-PqXBSe9ttBqqKwDHWTV2f9NfgD2yIp_</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Poorebrahim, Mansour</creator><creator>Abazari, Mohammad Foad</creator><creator>Sadeghi, Solmaz</creator><creator>Mahmoudi, Reza</creator><creator>Kheirollahi, Asma</creator><creator>Askari, Hassan</creator><creator>Wickström, Stina L.</creator><creator>Poortahmasebi, Vahdat</creator><creator>Lundqvist, Andreas</creator><creator>Kiessling, Rolf</creator><creator>Cid-Arregui, Angel</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20201001</creationdate><title>Genetically modified immune cells targeting tumor antigens</title><author>Poorebrahim, Mansour ; Abazari, Mohammad Foad ; Sadeghi, Solmaz ; Mahmoudi, Reza ; Kheirollahi, Asma ; Askari, Hassan ; Wickström, Stina L. ; Poortahmasebi, Vahdat ; Lundqvist, Andreas ; Kiessling, Rolf ; Cid-Arregui, Angel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-6e3fe0838d707e237cbcfed2ecf44017ce1cc72540b29a576bfaf2b72da3f1af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Genetically modified immune cell</topic><topic>Tumor antigen</topic><topic>‘Living’ therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poorebrahim, Mansour</creatorcontrib><creatorcontrib>Abazari, Mohammad Foad</creatorcontrib><creatorcontrib>Sadeghi, Solmaz</creatorcontrib><creatorcontrib>Mahmoudi, Reza</creatorcontrib><creatorcontrib>Kheirollahi, Asma</creatorcontrib><creatorcontrib>Askari, Hassan</creatorcontrib><creatorcontrib>Wickström, Stina L.</creatorcontrib><creatorcontrib>Poortahmasebi, Vahdat</creatorcontrib><creatorcontrib>Lundqvist, Andreas</creatorcontrib><creatorcontrib>Kiessling, Rolf</creatorcontrib><creatorcontrib>Cid-Arregui, Angel</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Pharmacology & therapeutics (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poorebrahim, Mansour</au><au>Abazari, Mohammad Foad</au><au>Sadeghi, Solmaz</au><au>Mahmoudi, Reza</au><au>Kheirollahi, Asma</au><au>Askari, Hassan</au><au>Wickström, Stina L.</au><au>Poortahmasebi, Vahdat</au><au>Lundqvist, Andreas</au><au>Kiessling, Rolf</au><au>Cid-Arregui, Angel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetically modified immune cells targeting tumor antigens</atitle><jtitle>Pharmacology & therapeutics (Oxford)</jtitle><date>2020-10-01</date><risdate>2020</risdate><volume>214</volume><spage>107603</spage><epage>107603</epage><pages>107603-107603</pages><artnum>107603</artnum><issn>0163-7258</issn><eissn>1879-016X</eissn><abstract>Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such ‘living’ therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.pharmthera.2020.107603</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-7258 |
| ispartof | Pharmacology & therapeutics (Oxford), 2020-10, Vol.214, p.107603-107603, Article 107603 |
| issn | 0163-7258 1879-016X |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_470418 |
| source | SWEPUB Freely available online; ScienceDirect Journals (5 years ago - present) |
| subjects | Genetically modified immune cell Tumor antigen ‘Living’ therapy |
| title | Genetically modified immune cells targeting tumor antigens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T19%3A39%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetically%20modified%20immune%20cells%20targeting%20tumor%20antigens&rft.jtitle=Pharmacology%20&%20therapeutics%20(Oxford)&rft.au=Poorebrahim,%20Mansour&rft.date=2020-10-01&rft.volume=214&rft.spage=107603&rft.epage=107603&rft.pages=107603-107603&rft.artnum=107603&rft.issn=0163-7258&rft.eissn=1879-016X&rft_id=info:doi/10.1016/j.pharmthera.2020.107603&rft_dat=%3Cproquest_swepu%3E2415294564%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2415294564&rft_id=info:pmid/&rft_els_id=S0163725820301339&rfr_iscdi=true |